col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


105 Results       Page 1

 [1] 
Elsevier: Pharmacological Research
  original article Date Title Authors   All Authors
1 [GO] 2022―Nov―04 Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19 Sara Epis, Ilaria Varotto-Boccazzi, Alessandro Manenti, Diego Rubolini, Paolo Gabrieli, Giulia Maria Cattaneo, et al. (+13)
2 [GO] 2022―Oct―13 Glucocorticoids and COVID-19 Stefano Bruscoli, Pier Giorgio Puzzovio, Maria Zaimi, Katerina Tiligada, Francesca Levi-Schaffer, Carlo Riccardi
3 [GO] 2022―Sep―30 Beneficial Effects of Vitamin C and L-Arginine in the Treatment of Post-Acute Sequelae of COVID-19 Gaetano Santulli, Valentina Trimarco, Bruno Trimarco, Raffaele Izzo
4 [GO] 2022―Sep―16 Pharmacological targeting of HMGB-1 translocation: A potential therapeutic strategy for COVID-19 Vahid Bagheri
5 [GO] 2022―Sep―13 Concerns About Methodology on “Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19 Renin Chang, Cheuk-Kwan Sun, Yao-Min Hung
6 [GO] 2022―Sep―09 Comment on ‘Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis’ by Tseng et al. Pei-Yun Shih, Su-Boon Yong, James Cheng-Chung Wei
7 [GO] 2022―Sep―09 Treating COVID-19 with NRICM101 and NRICM102 - author’s reply 3 Yu-Hwei Tseng, Sunny Jui-Shan Lin, Ming-Yung Lee, Yi-Chang Su
8 [GO] 2022―Sep―09 Treating COVID-19 with NRICM101 and NRICM102 - author’s reply Sunny Jui-Shan Lin, Ming-Yung Lee, Yu-Hwei Tseng, Yi-Chang Su
9 [GO] 2022―Sep―09 Treating COVID-19 with NRICM101 and NRICM102 - author’s reply 2 Ming-Yung Lee, Yu-Hwei Tseng, Sunny Jui-Shan Lin, Yi-Chang Su
10 [GO] 2022―Sep―08 The true effect of traditional Chinese medicine on the clinical outcome of hospitalized patients with COVID-19? Chi-Kuei Hsu, Chih-Cheng Lai, Jui-Hsiang Wang
11 [GO] 2022―Sep―05 Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis Wen-Chi Wei, Chia-Ching Liaw, Keng-Chang Tsai, Chun-Tang Chiou, Yu-Hwei Tseng, Wen-Fei Chiou, et al. (+8)
12 [GO] 2022―Aug―23 Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis Yu-Hwei Tseng, Sunny Jui-Shan Lin, Sheng-Mou Hou, Chih-Hung Wang, Shun-Ping Cheng, Kung-Yen Tseng, et al. (+23)
13 [GO] 2022―Jun―30 Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy Yiran E. Li, Amir Ajoolabady, Muralikrishnan Dhanasekaran, Jun Ren
14 [GO] 2022―Jun―09 Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever Francesca Marinelli, Chiara Caporilli, Annachiara Titolo, Donato Rigante, Susanna Esposito
15 [GO] 2022―May―20 Estimating the effectiveness of remdesivir on risk of COVID-19 mortality: The role of observational data Andrea Giacomelli, Alessandro Cozzi-Lepri, Giacomo Casalini, Letizia Oreni, Anna Lisa Ridolfo, Spinello Antinori
16 [GO] 2022―Apr―01 COVID-19 and The Promise of Small Molecule Therapeutics: Are There Lessons to be Learnt? Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, Christina Li Lin Chai
17 [GO] 2022―Mar―11 Timely Treatment and Higher Compliance to Traditional Chinese Medicine: New Influencing Factors for Reducing Severe COVID-19 based on Retrospective Cohorts in 2020 and 2021 Ying Zhang, Yangyang Liu, Ming Li, Shaohua Feng, Xiuyang Li, Zezheng Gao, et al. (+2)
18 [GO] 2021―Dec―31 Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: a systematic review and meta-analysis of randomised trials Elisabetta Caiazzo, Asma O.M. Rezig, Dario Bruzzese, Armando Ialenti, Carla Cicala, John G.F. Cleland, et al. (+3)
19 [GO] 2021―Dec―23 Corrigendum to “DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic Alessandro Villa, Electra Brunialti, Jessica Dellavedova, Clara Meda, Monica Rebecchi, Matteo Conti, et al. (+5)
20 [GO] 2021―Nov―19 Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761] Li Runfeng, Hou Yunlong, Huang Jicheng, Pan Weiqi, Ma Qinhai, Shi Yongxia, et al. (+12)
21 [GO] 2021―Nov―16 DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. Alessandro Villa, Electra Brunialti, Jessica Dellavedova, Clara Meda, Monica Rebecchi, Matteo Conti, et al. (+5)
22 [GO] 2021―Oct―29 Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019 Zhi-Yu Li, Zhi-Jun Xie, Hai-Chang Li, Jian-Jian Wang, Xiang-Hui Wen, Shou-Yuan Wu, et al. (+27)
23 [GO] 2021―Aug―26 Sex-tailored pharmacology and COVID-19: next steps towards appropriateness and health equity Andrea Spini, Valentina Giudice, Vincenzo Brancaleone, Maria Grazia Morgese, Silvia De Francia, Amelia Filippelli, et al. (+5)
24 [GO] 2021―Aug―14 Identification of Natural Compounds as SARS-CoV-2 Entry Inhibitors by Molecular Docking-based Virtual Screening with Bio-layer Interferometry Dingqi Zhang, Sami Hamdoun, Ruihong Chen, Lijun Yang, Chi Kio Ip, Yuanqing Qu, et al. (+6)
25 [GO] 2021―Jun―03 Remdesivir in moderate to severe COVID-19: a matter of time? Cecilia Bonazzetti, Andrea Giacomelli, Martina Pavia, Chiara Fusetti, Martina Gerbi, Francesco Petri, et al. (+4)
26 [GO] 2021―May―09 A bibliometric study of COVID-19 research in Web of Science Meiming Su, Suowen Xu, Jianping Weng
27 [GO] 2021―Apr―07 Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] Emilio Di Maria, Paolo Martini, Massimo Gennarelli
28 [GO] 2021―Apr―02 A new stratification model for a population health risk assessment, based on a large cohort of patients infected by Covid-19 Roberto Blaco, Olivia Leoni, Gjiliola Cukaj, Michele Ercolanoni, Carla Carnovale
29 [GO] 2021―Mar―27 Understanding the Heart-Brain Axis Response in COVID-19 patients: a Suggestive Perspective for Therapeutic Development Vincenzo Lionetti, Sveva Bollini, Raffaele Coppini, Andrea Gerbino, Alessandra Ghigo, Guido Iaccarino, et al. (+16)
30 [GO] 2021―Mar―06 Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications Stephanie L. Harrison, Benjamin J.R. Buckley, Deirdre A. Lane, Paula Underhill, Gregory Y.H. Lip
31 [GO] 2021―Feb―16 International policies and challenges on the legalization of traditional medicine/herbal medicines in the fight against COVID-19 Yin Xiong, Min Gao, Bert van Duijn, Hoyoung Choi, Frits van Horssen, Mei Wang
32 [GO] 2021―Jan―30 Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study Jiandong Zhou, Sharen Lee, Cosmos Liutao Guo, Carlin Chang, Tong Liu, Keith Sai Kit Leung, et al. (+4)
33 [GO] 2020―Dec―25 CONSUMPTION OF ANTIBIOTICS AT AN ITALIAN UNIVERSITY HOSPITAL DURING THE EARLY MONTHS OF THE COVID-19 PANDEMIC: WERE ALL ANTIBIOTIC PRESCRIPTIONS APPROPRIATE? Andrea Giacomelli, Anna Lisa Ridolfo, Letizia Oreni, Stefania Vimercati, Maria Albrecht, Dario Cattaneo, et al. (+4)
34 [GO] 2020―Dec―24 Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 Emilio Di Maria, Paolo Martini, Massimo Gennarelli
35 [GO] 2020―Dec―17 Saliva sampling for chasing SARS-CoV-2: A Game-changing strategy Elisa Borghi, Valentina Massa, Daniela Carmagnola, Claudia Dellavia, Chiara Parodi, Emerenziana Ottaviano, et al. (+5)
36 [GO] 2020―Dec―16 Methodological education in response to the quality of COVID-19 publications Felicita Andreotti, Cristina Gervasoni, Giuseppe Di Pasquale, Aldo P. Maggioni
37 [GO] 2020―Nov―13 Letter to the Editor in response to the articles ‘Lianhuaqingwen exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2)’ and ‘Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.’ Xi Huang, Qiulong Zhao, Liang Xia, Shaoqi Shi
38 [GO] 2020―Nov―09 Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study Nannan Shi, Bin Liu, Ning Liang, Yan Ma, Youwen Ge, Honggang Yi, et al. (+86)
39 [GO] 2020―Nov―05 Letter to the Editor in response to the article ‘Candidate drugs against SARS-CoV-2 and COVID-19 Ilaria Campesi, Andrea Montella, Flavia Franconi F
40 [GO] 2020―Oct―20 NARINGENIN IS A POWERFUL INHIBITOR OF SARS-CoV-2 INFECTION IN VITRO Nicola Clementi, Carolina Scagnolari, Antonella D’Amore, Fioretta Palombi, Elena Criscuolo, Federica Frasca, et al. (+6)
41 [GO] 2020―Oct―13 Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions Awortwe Charles, Cascorbi Ingolf
42 [GO] 2020―Aug―29 Chinese herbal medicine supplementation therapy on COVID-19 Mingyang Yu, Rongguang Zhang, Peng Ni, Guangcai Duan
43 [GO] 2020―Aug―15 Covid-19 Pandemic: a frontline hospital reorganization to cope with therapeutic and diagnostic emergency Giuseppe De Filippis, Laura Cavazzana, Alessandra Gimigliano, Mariagrazia Piacenza, Stefania Vimercati
44 [GO] 2020―Aug―10 Hanshiyi Formula, an approved medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study Jiaxing Tian, Shiyan Yan, Han Wang, Ying Zhang, Yujiao Zheng, Haoran Wu, et al. (+9)
45 [GO] 2020―Aug―08 Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial Mingzhong Xiao, Jiaxing Tian, Yana Zhou, Xi Xu, Xiaojun Min, Yi Lv, et al. (+22)
46 [GO] 2020―Aug―04 COVID-19: pharmacology and kinetics of viral clearance Nicola Farina, Giuseppe A. Ramirez, Rebecca De Lorenzo, Luigi Di Filippo, Caterina Conte, Fabio Ciceri, et al. (+2)
47 [GO] 2020―Jul―31 Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: a systematic review and meta-analysis of 40 studies and 25,278 patients Mengjiao Shao, XiaoMei Li, Fen Liu, Ting Tian, Junyi Luo, Yining Yang
48 [GO] 2020―Jul―12 Data to guide the application of the new WHO criteria for releasing COVID-19 patients from isolation Andrea Foppiani, Simona Bertoli, Alberto Battezzati, Gianvincenzo Zuccotti
49 [GO] 2020―Jul―09 Analysis on the Current Quality Standards of Chinese Materia Medica Used in COVID-19 Prevention and Treatment Yan-Hong Shi, Yu-Feng Huang, Wang Wang-Ying, Li Yang, Hua Zhou, Zhen Sang
50 [GO] 2020―Jul―09 The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2 Qinhai Ma, Minshan Qiu, Hongxia Zhou, Jie Chen, Xue Yang, Zhenxuan Deng, et al. (+8)
51 [GO] 2020―Jul―03 Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas Center, Milan Mariangela Allocca, Giacomo Maria Guidelli, Riccardo G. Borroni, Carlo Selmi, Alessandra Narcisi, Silvio Danese, Gionata Fiorino
52 [GO] 2020―Jul―02 Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis Xingjiang Xiong, Pengqian Wang, Kelei Su, William C. Cho, Yanwei Xing
53 [GO] 2020―Jun―30 Mortality in COVID-19 patients treated with ACEIs/ARBs: re-estimated meta-analysis results following the Mehra et al. retraction Ahmad Alamer, Ivo Abraham
54 [GO] 2020―Jun―30 Edaravone: a potential treatment for the COVID-19-induced inflammatory syndrome? Sandra E. Reznik, Amit K. Tiwari, Charles R. Ashby
55 [GO] 2020―Jun―27 Targeting inflammation and cytokine storm in COVID-19 Qianwen Huang, Xiumei Wu, Xueying Zheng, Sihui Luo, Suowen Xu, Jianping Weng
56 [GO] 2020―Jun―23 The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19 Yu-Xi Huang, Wen-Xiao Wang, Sai Zhang, Yu-Ping Tang, Shi-Jun Yue
57 [GO] 2020―Jun―20 Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients Hu-Dan Pan, Xiao-Jun Yao, Wan-Ying Wang, Hung-Yan Lau, Liang Liu
58 [GO] 2020―Jun―18 Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019 Xin Li, Yi Yang, Lancong Liu, Xuefeng Yang, Xiaobo Zhao, Yan Li, et al. (+8)
59 [GO] 2020―Jun―17 Statins and other drugs: Facing COVID-19 as a vascular disease Fabian Sanchis-Gomar, Carme Perez-Quilis, Emmanuel J. Favaloro, Giuseppe Lippi
60 [GO] 2020―Jun―09 East meets West in COVID-19 therapeutics Shanshan Wang, Xian Zeng, Yali Wang, Yufen Zhao, Weiping Chen, Yu Zong Chen
61 [GO] 2020―Jun―04 Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension? Ying Huang, Changming Xie, Xiaoke Chen, Qianhui Hong, Hui Huang
62 [GO] 2020―Jun―02 Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19 Sida Jiang, Qiuji Cui, Bingwei Ni, Yingying Chen, Ying Tan, Weiping Chen, Yu Zong Chen
63 [GO] 2020―May―29 Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study Vincenzo Russo, Marco Di Maio, Emilio Attena, Angelo Silverio, Fernando Scudiero, Dario Celentani, et al. (+2)
64 [GO] 2020―May―28 Angiotensin receptor blockers for the treatment of covid-19 and its comorbidities Juan M. Saavedra
65 [GO] 2020―May―28 Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system Shuofeng Yuan, Jasper F.W. Chan, Kenn K.H. Chik, Chris C.Y. Chan, Jessica O.L. Tsang, Ronghui Liang, et al. (+10)
66 [GO] 2020―May―25 COVID-19 and Kawasaki Disease in Children Suowen Xu, Mingwu Chen, Jianping Weng
67 [GO] 2020―May―23 Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study Maurizio Viecca, Dejan Radovanovic, Giovanni Battista Forleo, Pierachille Santus
68 [GO] 2020―May―23 Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications Peng-jiao An, Zhun Zhu Yi, Li-ping Yang
69 [GO] 2020―May―22 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study Andrea Giacomelli, Anna Lisa Ridolfo, Laura Milazzo, Letizia Oreni, Dario Bernacchia, Matteo Siano, et al. (+19)
70 [GO] 2020―May―21 Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19) Yu-Feng Huang, Chen Bai, Fan He, Ying Xie, Hua Zhou
71 [GO] 2020―May―20 A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) Fangfang Huang, Ying Li, Elaine Lai-Han Leung, Xiaohua Liu, Kaifeng Liu, Qu Wang, et al. (+6)
72 [GO] 2020―May―20 Letter to the Editor in response to the article “Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?” Gabriele Ceccarelli, Katiuscia Nardi, Francesca Marchesani
73 [GO] 2020―May―15 ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis Xue Zhang, Jiong Yu, Li-ya Pan, Hai-yin Jiang
74 [GO] 2020―May―13 The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Eugenia Quiros Roldan, Giorgio Biasiotto, Paola Magro, Isabella Zanella
75 [GO] 2020―May―13 COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Marijana Tadic, Cesare Cuspidi, Giuseppe Mancia, Raffaella Dell’Oro, Guido Grassi
76 [GO] 2020―May―13 Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter’s and Gitelman’s syndrome patients Lorenzo A. Calò, Giovanni Bertoldi, Paul A. Davis
77 [GO] 2020―May―11 Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis Ming Liu, Ya Gao, Yuan Yuan, Kelu Yang, Shuzhen Shi, Junhua Zhang, Jinhui Tian
78 [GO] 2020―May―11 Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status Spinello Antinori, Maria Vittoria Cossu, Anna Lisa Ridolfo, Roberto Rech, Cecilia Bonazzetti, Gabriele Pagani, et al. (+21)
79 [GO] 2020―May―11 Does lopinavir really inhibit SARS-CoV-2? Dario Cattaneo, Mario Corbellino, Emilio Clementi, Massimo Galli, Agostino Riva, Cristina Gervasoni
80 [GO] 2020―May―07 Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic Maciej Banach, Peter E. Penson, Zlatko Fras, Michal Vrablik, Daniel Pella, Željko Reiner, et al. (+4)
81 [GO] 2020―May―06 The CoV-2 outbreak: how hematologists could help to fight Covid-19 Sara Galimberti, Chiara Baldini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi, et al. (+8)
82 [GO] 2020―May―05 The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence Dan Zhang, Bing Zhang, Jin-Tao Lv, Ri-Na Sa, Xiao-Meng Zhang, Zhi-Jian Lin
83 [GO] 2020―May―03 The pros and cons of traditional Chinese medicines in the treatment of COVID-19 Yali Wang, Xian Zeng, Yufen Zhao, Weiping Chen, Yu Zong Chen
84 [GO] 2020―Apr―30 Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis Han Zhong, Yan Wang, Zai-Li Zhang, Yang-Xi Liu, Ke-Jia Le, Min Cui, et al. (+4)
85 [GO] 2020―Apr―30 Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): in silico and experimental study Ruocong Yang, Hao Liu, Chen Bai, Yingchao Wang, Xiaohui Zhang, Rui Guo, et al. (+7)
86 [GO] 2020―Apr―30 Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management Mina T. Kelleni
87 [GO] 2020―Apr―30 Epidemiological and Clinical Characteristics Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province in 2020 Yi Zheng, Chang Xiong, Yuquan Liu, Xin Qian, Yijun Tang, Liang Liu, et al. (+2)
88 [GO] 2020―Apr―30 Current targeted therapeutics against COVID-19: based on first-line experience in china Yue Zhang, Qianhao Xu, Zhuoyan Sun, Lei Zhou
89 [GO] 2020―Apr―30 Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway Qinhai Ma, Weiqi Pan, Runfeng Li, Bin Liu, Chufang Li, Yuqi Xie, et al. (+9)
90 [GO] 2020―Apr―30 Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 Solomon Habtemariam, Seyed Fazel Nabavi, Saeid Ghavami, Cosmin Andrei Cismaru, Ioana Berindan Neagoe, Seyed Mohammad Nabavi
91 [GO] 2020―Apr―29 Candidate drugs against SARS-CoV-2 and COVID-19 Dwight L. McKee, Ariane Sternberg, Ulrike Stange, Stefan Laufer, Cord Naujokat
92 [GO] 2020―Apr―29 NSAIDs in patients with viral infections, including Covid-19: victims or perpetrators? Annalisa Capuano, Cristina Scavone, Giorgio Racagni, Francesco Scaglione
93 [GO] 2020―Apr―22 Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection Roberto Maggio, Giovanni U. Corsini
94 [GO] 2020―Apr―21 Darunavir does not prevent SARS-CoV-2 infection in HIV patients Agostino Riva, Federico Conti, Dario Bernacchia, Laura Pezzati, Salvatore Sollima, Stefania Merli, et al. (+5)
95 [GO] 2020―Apr―15 Angiotensin Receptor Blockers and 2019-nCoV Juan M. Saavedra
96 [GO] 2020―Apr―14 Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome? Gian Marco Casillo, Adel Abo Mansour, Federica Raucci, Anella Saviano, Nicola Mascolo, Asif Jilani Iqbal, Francesco Maione
97 [GO] 2020―Apr―14 Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor Yanwei Li, Wei Zhou, Li Yang, Ran You
98 [GO] 2020―Apr―11 Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) Farshad Abedi, Ramin Rezaee, Gholamreza Karimi
99 [GO] 2020―Apr―11 Statins in coronavirus outbreak: it’s time for experimental and clinical studies Maurizio Bifulco, Patrizia Gazzerro
100 [GO] 2020―Apr―03 The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good Paul E. Gray, Yvonne Belessis
101 [GO] 2020―Apr―03 Reply to “The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good” Ai-Hua Zhang, Jun-Ling Ren, Xi-Jun Wang
102 [GO] 2020―Apr―02 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials Mekonnen Sisay
103 [GO] 2020―Mar―25 Corrigendum to “Traditional Chinese medicine for COVID-19 treatment” [Pharmacol. Res. 155 (2020) 104743] Jun-ling Ren, Ai-Hua Zhang, Xi-Jun Wang
104 [GO] 2020―Mar―20 Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Li Runfeng, Hou Yunlong, Huang Jicheng, Pan Weiqi, Ma Qinhai, Shi Yongxia, et al. (+12)
105 [GO] 2020―Mar―04 Traditional Chinese Medicine for COVID-19 Treatment Jun-ling Ren, Ai-Hua Zhang, Xi-Jun Wang
 [1] 

105 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.006 sec